Thalidomide, well known for its potent teratogenicity, has been re-evaluated as a clinically
effective drug for the treatment of multiple myeloma. Although the direct target of thalidomide …

Thalidomide was sold worldwide as a sedative over 60 years ago, but it was quickly
withdrawn from the market due to its teratogenic effects. Thalidomide was later found to have …

Thalidomide, originally developed as a sedative drug, causes multiple defects due to severe
teratogenicity, but it has been re-purposed for treating multiple myeloma, and derivatives …

Cereblon (CRBN), originally identified as a gene associated with intellectual disability, was
identified as primary target of thalidomide. Accumulating evidence has shown that CRBN is …

Thalidomide was sold in the 1950s as a sedative and was also used by pregnant women to
treat morning sickness. It became notorious for causing severe birth defects and was …

Proteolysis targeting chimeras (PROTACs) hijacking the cereblon (CRBN) E3 ubiquitin
ligase have emerged as a novel paradigm in drug development. Herein we found that linker …

Thalidomide was first developed as a sedative around 60 years ago, but exhibited
teratogenicity, leading to serious defects such as limb deformities. Nevertheless, thalidomide …

It has been found that nonsense mutation R419X of cereblon (CRBN) is associated with
autosomal recessive non-syndromic mental retardation. Further experiments showed that …

Introduction Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase
has been extensively studied due to its involvement in many biological processes. It has …

Targeted protein degradation represents a rapidly growing area in drug discovery and
development. Moreover, small molecules that induce the targeted degradation of a given …